But the wandering-spider, or Phoneutria nigriventer, will be soon known for other reason. Biozeus, a private biotechnology company in Rio de Janeiro, is developing a cream for erectile dysfunction based on a peptide found in the spider’s venom. The project is in its last stages with human trials set to begin in a couple of months… Click here to original publication. Fonte: BBC.com…
First in vivo gene-editing drugs enter the clinic
The FDA posted strong approval numbers last year, rebounding from a steep drop in 2016. The agency’s Center for Drug Evaluation and Research (CDER) approved a total of 46 new drugs in 2017, the most since the peak of 59 in 1996 (FIG. 1; TABLE 1). This puts last year’s approval count well above the 5-year and 10-year averages (36 and 32, respectively)… Click here to original publication. Fonte: NATURE REVIEWS | DRUG DISCOVERY ADVANCE ONLINE PUBLICATION | 1…
Drugmakers cling to dual IL-13/IL-4 blockbuster hop
The recent failure of AstraZeneca’s interleukin-13 (IL-13) inhibitor tralokinumab to show efficacy in two phase 3 trials in asthma extends an already lengthy rap sheet against a therapeutic target that has confounded drug developers’ expectations. Despite widespread recognition of the central role IL-13 plays in mediating allergic disease, companies have struggled for more than a decade to produce clear-cut clinical evidence that targeting the cytokine will benefit patients… Click here to original publication. Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 1 JANUARY 2018…
Texas displays ‘Silicon Valley’ credentials to lure Brazilian biotechs
VelocityTX and Rio de Janeiro–based Outsource Brazil (OBr) have launched a new program to lure promising tech and biotech businesses from Brazil to San Antonio, Texas… Click here to original publication. Fonte: VOLUME 36 NUMBER 1 JANUARY 2018 NATURE BIOTECHNOLOGY…
With a free pass, CRISPR-edited plants reach market in record time
CRISPR–Cas9-edited plants can be cultivated and sold free from regulation, the US Department of Agriculture (USDA) is making increasingly clear. The agency gave a free pass to Camelina sativa, or false flax, with enhanced omega-3 oil… Click here to original publication. Fonte: VOLUME 36 NUMBER 1 JANUARY 2018 NATURE BIOTECHNOLOGY…
Upcoming market catalysts in Q1 2018
Potential market catalysts in the first quarter of 2018 include important top-line clinical trial results for rigerimod (developed by ImmuPharma and SymBio) for systemic lupus… Click here to original publication. Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JANUARY 2018 …
NEWS & ANALYSIS
First in vivo gene-editing drugs enter the clinic Sangamo Therapeutics has started dosing patients with gene-editing drugs that are administered directly into the blood. Para acessar a publicação na íntegra clique aqui Click here to original publication. Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JANUARY 2018…